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Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892-0720Human respiratory syncytial virus (RSV) is a highly
infectious, ubiquitous virus that is the leading cause of
serious respiratory tract disease in children under one
year of age worldwide (for reviews, see Brandenburg et
al., 2001; Collins et al., 1999, 2001; Crowe et al., 1997;
Dudas and Karron, 1998). RSV accounts for nearly one-
quarter of hospitalizations due to pediatric respiratory
tract disease, and in the United States accounts for
85,000 to 144,000 hospitalizations annually in infants of
less than one year of age (Shay et al., 1999). RSV rein-
fection is gaining recognition as an important cause of
disease in adults, especially the elderly, and in immuno-
compromised individuals. An RSV vaccine is not yet
available. The primary need is for the pediatric popula-
tion, with the second major target population being the
elderly, for which RSV has an impact approaching that of
nonpandemic influenza virus. Most of the candidate vac-
cines described below involve expression from cDNA,
which is called reverse genetics (Berg, 1993).
RSV is an enveloped virus of the Paramyxovirus family
(order Mononegavirales). Its genome is a single nega-
tive-sense RNA of 15.2 kilobases that is transcribed into
10 mRNAs encoding 11 proteins (the M2 mRNA encodes
two proteins, M2-1 and M2-2 from overlapping open
reading frames (ORFs)) (Fig. 1). N, P, L, and M2-1 are the
nucleocapsid/polymerase proteins; M2-2 appears to play
a regulatory role in RNA synthesis; M is a matrix protein;
NS1 and NS2 are nonstructural proteins recently identi-
fied as antagonists of the interferon-/-mediated anti-
viral state (Schlender et al., 2000); and SH, G, and F are
transmembrane glycoproteins. G and F are the only an-
tigens that induce neutralizing antibodies and are the
major protective antigens. Infectious recombinant RSV
can be produced from transfected plasmids expressing a
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204positive-sense copy of viral antigenomic RNA together
with the nucleocapsid/polymerase proteins (Collins et
al., 1995; Jin et al., 1998).
A number of characteristics of RSV biology and epide-
miology complicate vaccine development. RSV does not
replicate efficiently in vitro, and careful handling is nec-
essary to maintain infectivity. RSV exists in two antigenic
subgroups (A and B) that differ most prominently in the G
protein, and both subgroups would be desirable in an
RSV vaccine. Reinfection by RSV is common, although
disease is reduced: this indicates that natural immunity
is incomplete and poses a challenge to vaccination.
Because the peak incidence of serious RSV disease is at
2–7 months of age, a pediatric RSV vaccine should be
given shortly after birth. However, immune responses in
the very young infant are reduced due to immunological
immaturity (Delespesse et al., 1998; Murphy et al., 1986a)
and the immunosuppressive effects of maternally de-
rived RSV-specific serum IgG typically present in this age
group (Crowe et al., 2001).
The chimpanzee is the only experimental animal that
approaches the human in permissiveness to RSV repli-
cation and disease (Brandenburg et al., 2001; Belshe et
al., 1977; Collins et al., 1990; Whitehead et al., 1998) but
is limited in availability. Convenient experimental ani-
mals such as mice and cotton rats are nonnatural hosts
that are semipermissive for RSV replication and do not
exhibit authentic RSV disease. An accurate evaluation of
the safety and efficacy of a pediatric RSV vaccine can
only be made in clinical studies involving the target
population, namely RSV-naı¨ve 1- to 2-month-old infants
possessing maternally derived antibodies (Wright et al.,
2000).
Vaccine-associated disease potentiation and RSV pro-
tein vaccines. A Formalin-inactivated RSV (FI-RSV) vac-
cine that was evaluated in infants and children in the
1960s was found to be poorly protective and, unexpect-Received December 4, 20
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edly, was associated with an increased frequency and
severity of RSV disease upon subsequent natural infec-01; acc
tion (Crowe et al., 1997; Dudas and Karron, 1998; Open-
shaw et al., 2001). The idea that the immune response to
RSV antigens could increase RSV disease was unex-
pected, since natural RSV infection induces an immune
response that is protective, albeit incompletely, and re-
duces rather than enhances disease associated with
reinfection. Retrospective studies showed that FI-RSV
induced serum antibodies that bound RSV antigen but
did not efficiently neutralize the virus (Murphy et al.,
1986b), a finding that has been confirmed in experimen-
tal animals and likely explains the poor protective effi-
cacy. The original FI-RSV vaccinees also exhibited a
heightened RSV-specific lymphoproliferative response
(Kim et al., 1976). This is consistent with more recent
studies in mice and cotton rats, where disease potenti-
ation by FI-RSV was shown to depend on an increased
stimulation of Th2 CD4 T lymphocytes (Openshaw et al.,
2001; Connors et al., 1994; Graham et al., 1993). How this
mediates enhanced disease is not yet clear. In contrast,
passive transfer of serum antibodies from FI-RSV-immu-
nized animals to naı¨ve animals did not enhance disease
upon subsequent infection (Connors et al., 1992). FI-RSV
also was shown to be a poor inducer of CD8 T cells,
which is not unusual for a protein vaccine. This might
account for the heightened Th2 response to FI-RSV,
since recent studies in mice showed that CD8 T cells
down-regulate Th2 cells during the immune response to
RSV antigens (Hussell et al., 1997; Srikiatkhachorn and
Braciale, 19975). By this model, vaccines that do not
efficiently induce CD8 T cells, such as soluble antigens
like FI-RSV, would have the propensity to prime for en-
hanced disease. In contrast, the strong CD8 T cell
response characteristic of natural RSV infection could
account for the absence of disease potentiation. It also
has been suggested that the G protein has unusual
antigenic properties that favor an atypical inflammatory
response (Hancock et al., 1996).
Disease potentiation in the rodent models also has
been observed with experimental vaccines consisting of
purified RSV F and G protein, and thus indeed might be
a general concern with RSV protein vaccines (Graham et
al., 1993; Connors et al., 1992; Hancock et al., 1996;
Murphy et al., 1990). This might be improved by use of an
adjuvant that alters the T lymphocyte response (Prince et
al., 2001), although none are presently approved for hu-
man use. Unfortunately, it may be difficult to convincingly
establish that immunization with a candidate pediatric
protein vaccine does not potentiate RSV disease since
studies in experimental animals are of limited predictive
value for the human, and clinical studies in RSV-naı¨ve
infants likely would pose unacceptable risk. However,
disease potentiation is not observed if FI-RSV is admin-
istered as a boost to animals that have already been
infected with RSV (Graham et al., 1993; Waris et al., 1997).
Thus, while an RSV protein vaccine might not be appro-
priate as the first immunization for the young infant, it
should be suitable to boost immunity in individuals who
have already experienced one or more natural infections.
Recipients of such a protein vaccine could include the
elderly as well as individuals at high risk for RSV disease
such as due to congenital heart disease or chronic lung
disease.
Clinical trials have been reported for two RSV protein
vaccines, all involving vaccinees of 24 months or older.
The first is PFP, which consists of full-length F protein
purified from RSV-infected cells (Hancock et al., 1995).
PFP has been shown to be safe and moderately immu-
nogenic in, for example, children with chronic lung dis-
ease (Groothuis et al., 1998) and the elderly (Falsey and
Walsh, 1997). The second protein vaccine is BBG2Na, a
FIG. 1. Diagrams illustrating the RSV gene map (negative-sense RNA, 3 to 5) and examples of gene deletions that result in viable, attenuated
vaccine candidates. The 10 RSV genes are shown as boxes: each encodes a single mRNA and is flanked by short gene-start and gene-end signals
that guide sequential transcription. The genes are separated by short intergenic regions except for the M2 and L genes, which overlap (Collins et
al., 2001). The M2 mRNA contains two overlapping ORFs, M2-1 and M2-1, shown as small rectangles within the M2 box. The thin horizontal lines at
the left- and right-hand ends represent the 3-leader and 5-trailer extragenic regions. Examples of viable gene-deletion mutants are shown with the
deleted gene(s) or ORF indicated in black (Bermingham and Collins, 1999; Jin et al., 2000; Teng et al., 2001). The relative efficiency of replication in
cell culture and in the respiratory tract of seronegative chimpanzees is scored from 0 to 5. nd: not done. The viruses are arranged from the top in
the order of increasing attenuation in chimpanzees or rodents.
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recombinant protein produced in bacteria that consists
of amino acids 130–230 of the RSV G protein, comprising
a central antigenic domain, fused to the C-terminal end
of an albumin-binding domain of streptococcal G protein
(Power et al., 2001a). BBG2Na was safe and moderately
immunogenic in adults (Power et al., 20001b). Because
the BBG2Na vaccine is produced in bacteria, its G moiety
is devoid of glycosylation, and evidence has been pre-
sented that this may somehow preclude disease poten-
tiation (Power et al., 2001a, 2001c). Other experimental
RSV protein vaccines exist, including a baculovirus-ex-
pressed chimeric protein created by fusing the F and G
ORFs (Kakuk et al., 1993), as well as synthetic peptides:
these other protein vaccines are less far along in devel-
opment and would follow the same principles as PFP
and BBG2Na.
Live-attenuated RSV vaccines. A live-attenuated RSV
vaccine administered intranasally would mimic natural
infection without causing disease. The lack of disease
potentiation associated with RSV infection is a critical
safety advantage of the live vaccine strategy (Wright et
al., 2000; Waris et al., 1997). The mucosal route of immu-
nization also has the advantage of directly stimulating
local immunity and of reducing the immunosuppressive
effects of maternally derived antibodies (Crowe et al.,
1995). It is anticipated that a live RSV vaccine would be
administered two or three times during the first year of
life to boost immunity. A live RSV vaccine also could be
used as a vaccine for older seropositive individuals but
would have to be less attenuated than one for pediatric
use (Gonzalez et al., 2000).
Development of a live-attenuated RSV vaccine began
in the 1960s using conventional methods such as exten-
sive passage in vitro or chemical mutagenesis (Crowe et
al., 1997; Dudas and Karron, 1998). The most promising
mutants were made by subjecting wild-type RSV (strain
A2, subgroup A) to extensive cold-passage in vitro, re-
sulting in a moderately attenuated mutant called cp-RSV
that was then subjected to two rounds of chemical mu-
tagenesis to yield temperature-sensitive (ts) derivatives.
Several promising mutants, cpts-248/955, cpts-530/1030,
cpts-530/1009, and cpts-248/404, were evaluated in se-
ropositive children and older seronegative children, and
cpts-248/404 was deemed to be sufficiently attenuated to
be evaluated in 1- to 2-month-old RSV-naı¨ve infants, the
target vaccine age group (Wright et al., 2000). In this age
group, more than 80% of vaccinees were infected by
cpts-248/404, shed a moderate amount of virus, had a
significant rise in RSV-specific serum IgA antibodies, and
were highly resistant to reinfection with a second vac-
cine dose given 1 month later. The antibody response to
the G protein was more frequent and of greater magni-
tude than that to the F protein. However, a majority of
vaccinees experienced brief nasal congestion following
the initial immunization, indicating that the virus should
be further attenuated. Also, a single individual shed a
low, sporadic amount of virus with partial loss of the ts
and attenuation phenotypes, indicating that a greater
level of phenotypic stability would be desirable. Impor-
tantly, these studies provide evidence that effective im-
munization of young infants with a live RSV vaccine is
feasible.
The strategy shifted to employ reverse genetics to
systematically introduce attenuating mutations into in-
fectious recombinant RSV strain A2. The cp-RSV and
cpts-RSV mutants described above were sequenced in
their entirety. Identified mutations were evaluated phe-
notypically by introduction into the wild-type recombinant
virus (Collins et al., 1999). The cp-RSV mutant had five
amino acid substitutions in the N, F, and L proteins, and
each of the cpts-RSV mutants mentioned above had in
addition a unique set of two ts attenuating point muta-
tions. These involved various amino acid substitutions in
the L polymerase protein as well as a single noncoding
nucleotide change in the transcription gene-start signal
of the M2 gene. Because RSV does not grow robustly in
vitro, preferable attenuating mutations are ones that re-
strict replication in vivo but not in vitro, permitting effi-
cient vaccine production. ts mutations fulfill this require-
ment because growth in vitro can be performed at re-
duced, permissive temperature. ts mutations also have
the advantage of preferentially restricting replication in
the warmer lower respiratory tract, reducing the risk of
serious disease.
The deletion of nonessential genes provides another
method of attenuation, one that should be very stable.
Remarkably, five RSV genes, namely NS1, NS2, SH, G,
and M2-2, can be deleted or silenced individually and in
certain combinations without much effect on virus yield
in vitro (Fig. 1) (Bermingham and Collins, 1999; Jin et al.,
2000; Karron et al., 1997; Teng et al., 2001). Deletion of the
G gene would be unlikely to be useful since G was the
antigen that elicited the greatest and most frequent re-
sponse in infants and since virus lacking G appears was
over-attenuated in vivo (Karron et al., 1997; Teng et al.,
2001). The other deletion mutants exhibited a range of
attenuation in chimpanzees. In comparison to cpts-248/
404, they could be ranked in order of increasing attenu-
ation as follows: SH  NS2  cpts-248/404 
NS1  M2-2 (Teng et al., 2001). Thus, these gene
deletions represent promising attenuating mutations for
vaccine purposes, either on their own or in combination
with point mutations described previously. A virus such
as NS2 that is less attenuated than cpts-248/404 might
be a vaccine candidate for seropositive individuals in
whom cpts-248/404 is over-attenuated (Gonzalez et al.,
2000).
Another method of attenuation is based on bovine RSV
(BRSV), a closely related animal counterpart of human
RSV that is attenuated in primates due to a natural host
range restriction (Buchholz et al., 2000). BRSV itself is
over-attenuated and insufficiently immunogenic in sero-
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negative chimpanzees (Buchholz et al., 2000). Growth
was improved by replacing the G and F genes of BRSV
with their human RSV counterparts, although the result-
ing chimeric virus remained over-attenuated (Buchholz et
al., 2000). The systematic replacement of additional
BRSV genes with their human RSV counterparts should
yield viruses with a range of growth properties that can
be evaluated as vaccines. Host range recombinants,
such as deletion mutants, would be anticipated to be
phenotypically stable, as discussed elsewhere (Buch-
holz et al., 2000; Schmidt et al., 2000).
Thus, four types of attenuating mutations are available
for insertion in various combinations into recombinant
RSV: the non-ts cp-RSV point mutations; the ts point
mutations in the L protein and M2-1 gene-start signal
identified in the cpts-RSV mutants; the gene deletions;
and host-range-restrictive BRSV genes. The cp and ts
amino acid point mutations in the biologically derived
viruses each involved a single nucleotide substitution,
and in many cases it was possible to introduce the
attenuating amino acid assignment into recombinant vi-
rus using two nucleotide changes relative to wild-type.
This should greatly reduce the frequency of reversion to
the wild-type assignment, although it does not preclude
mutation by single nucleotide substitution to another
assignment with possible reduction in attenuation.
Figure 2 shows an example of a recombinant vaccine
candidate, designated rA2cp248/404/1030/SH, that is a
recombinant version of cpts-248/404 that has been fur-
ther attenuated by the inclusion of an additional ts mu-
tation, called 1030, from cpts-530/1030 as well as dele-
tion of the SH gene. This virus was more ts and attenu-
ated and resulted in a lower level of virus shedding in
seronegative children compared to cpts-248/404 and
represents a promising vaccine candidate (R. Karron,
unpublished data). This illustrates how attenuating mu-
tations from various viruses can be combined in desired
combinations to fine-tune the level of attenuation. Our
experience is that attenuation can be fine-tuned in a
reasonably systematic way, although the level of attenu-
ation specified by a combination of attenuating muta-
tions is not always the sum of the individual mutations,
and some trial and error is involved. A few combinations
of point mutations in L or of gene deletions have not
yielded viable virus (Jin et al., 2000; Whitehead et al.,
1999a). A recombinant vaccine virus constructed using
identified mutations would thus have a defined basis of
attenuation that can be readily monitored during produc-
tion and use, and cDNA provides a stable vaccine seed.
Additional means of attenuation of recombinant RSV
can be devised. To date, a number of attenuating muta-
tions have been identified by trial and error, including
point mutations in the L protein, a point mutation in the
leader region, and C-terminal deletions of the M2-1 pro-
tein (Tang et al., 2001). Based on studies with vesicular
stomatitis virus (VSV), attenuation can be achieved by
changing the gene order (Wertz et al., 1998). This strategy
could be applied to RSV provided that it does not reduce
the efficiency of growth in vitro, which otherwise could
interfere with vaccine production. An attenuating muta-
tion identified in one mononegavirus sometimes can be
“transferred” to another, particularly if it involves a con-
served residue. For example, an attenuating point muta-
tion in the Sendai virus C protein was transferred to the
corresponding position in the C protein of recombinant
human parainfluenza virus type 3 (HPIV3), resulting in
attenuation of the HPIV3 recipient (Durbin et al., 1999).
Reverse genetics was used to expedite development
of an RSV subgroup B vaccine, which faced the obsta-
cles of a lack both of promising vaccine candidates and
of a recombinant recovery system. Replacement of the G
and F genes of recombinant RSV A2 (subgroup A) with
their counterparts of strain B1 of subgroup B produced a
wild-type-like chimeric AB virus bearing the protective
antigens of subgroup B (Whitehead et al., 1999b). Atten-
uated AB viruses were readily produced using attenu-
ated versions of the A2 backbone and are in preparation
for clinical evaluation. Alternatively, the subgroup B G
gene, representing the more divergent protective anti-
gen, can be expressed as an added gene from a recom-
binant subgroup A virus (Jin et al., 1998).
Reverse genetics was used to increase the efficiency
of protective antigen expression by moving the G and F
genes from their natural positions as the seventh and
eighth genes in the gene order to promoter-proximal
positions, resulting in an increase in their expression (C.
Krempl, B. R. Murphy, and P. L .Collins, unpublished
results). It also will be of interest to investigate whether
modifying the codon usage of the F and G mRNAs to
employ alternative codons associated with increased
translational efficiency can promote more efficient ex-
pression of these protective antigens than the wild-type
virus. Interestingly, silencing the M2-2 ORF resulted in a
virus in which transcription and antigen expression was
increased, whereas RNA replication and virus produc-
tion were decreased. This suggests that, in a wild-type
infection, the M2-2 protein down-regulates transcription
and up-regulates RNA replication. Ablation of this puta-
tive regulatory function provides a novel phenotype that
might increase vaccine immunogenicity.
In principle, a recombinant RSV vaccine virus could be
FIG. 2. Gene map of rA2cp248/404/1030SH, a recombinant live-
attenuated RSV vaccine candidate that contains five point mutations
derived from cp-RSV (cp), three from cpts-248/404 (248, 404-M2, 404-L;
note that the last one does not appear to contribute to attenuation), one
from cpts-530/1009 (1030), and deletion of the SH gene (Collins et al.,
1995; Whitehead et al., 1999a).
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used as a vector for additional genes expressing protec-
tive antigens for heterologous pathogens such as HPIV3,
but in practice the addition of large genes can drastically
reduce the growth efficiency of RSV. However, small
genes are tolerated, and a number of recombinant RSVs
expressing immunomodulatory proteins such as cyto-
kines and chemokines are being evaluated as a means
of modifying and increasing the immune response to an
attenuated virus. For example, expression of granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) by
recombinant RSV following intranasal inoculation of mice
resulted in a dramatic increase in the number of pulmo-
nary dendritic cells and macrophages, as potential anti-
gen presenting cells (Bukreyev et al., 2001).
It also might be possible to alter recombinant RSV to
obtain improved characteristics of immunogenicity and
reduced pathogenesis. For example, the RSV G protein
was recently shown to be a structural and functional
mimic of fractalkine (Tripp et al., 2001), a proinflammatory
CX3C chemokine that mediates leukocyte migration and
adhesion. It is not yet known whether this mimicry inter-
feres with the host immune response or is a factor in
pathogenesis during RSV infection, but if so this activity
could be ablated by mutating the CX3C motif in G since
this does not affect infectivity or virus growth in vitro and
in mice (M. N. Teng and P. L. Collins, unpublished ob-
servations). As a second example, the G protein is ex-
pressed in part as a secreted form that arises from
translational initiation at the second methionyl codon.
The secreted form appears to prime for an atypical pul-
monary inflammatory response in mice (Johnson et al.,
1998). Therefore, it might be desirable to ablate its ex-
pression by mutation, which can be done without reduc-
ing infectivity or growth (Teng et al., 2001). It also will be
interesting to determine whether deletion of the NS1 and
NS2 genes, which encode antagonists of the interferon-
/-mediated antiviral state, affects the immune re-
sponse in humans.
Vectored RSV vaccines. This strategy is to express the
G and F neutralization antigens in vivo from an inocu-
lated recombinant vector. This approach was evaluated
initially with recombinant vaccinia viruses expressing the
RSV F or G protein. These recombinants were highly
immunogenic and protective in mice and cotton rats, but
when administered parenterally to chimpanzees they
induced low to moderate levels of RSV-neutralizing anti-
bodies and conferred inconsistent protection (Crowe et
al., 1997). Replication-competent adenovirus expressing
the F protein also was immunogenic and protective in
rodents and dogs, but did not induce significant resis-
tance to RSV infection in a chimpanzee (Crowe et al.,
1997).
Salmonella and staphylococcus have been investi-
gated as possible live recombinant vectors for RSV an-
tigens, although development is at an early phase (Cano
et al., 2000). DNA vaccines have been shown to be
immunogenic and protective in mice (Li et al., 2000).
However, DNA vaccines typically are not highly immuno-
genic on their own in primates and humans, usually are
given parenterally rather than topically, are readily sup-
pressed by existing antibodies, and require one or more
boosts that would be difficult to administer in the short
time window between birth and the peak of serious RSV
disease.
Heterologous mononegaviruses have been explored
as vectors for RSV antigens. One promising example is
based on a chimera between HPIV3 and its antigenically
related bovine counterpart, BPIV3. BPIV3 is attenuated in
primates due to a natural host range restriction. It has
been evaluated as a vaccine against HPIV3 and was
found to be immunogenic, safe, and genetically stable in
seronegative infants and children (Karron et al., 1996).
Since HPIV3 and BPIV3 have antigenic differences, the
bovine virus was next modified by reverse genetics so
that its major protective antigen genes F and HN (the
functional counterparts of RSV F and G) were replaced
with F and HN of HPIV3. This resulted in the chimeric
virus rB/HPIV3, a vaccine candidate for HPIV3 that com-
bines the major protective antigens of HPIV3 with the
attenuated backbone of BPIV3 (Schmidt et al., 2000) (Fig.
3). Next, the RSV G and F glycoproteins were inserted
singly or together into rB/HPIV3, with a promoter-proxi-
mal insertion site chosen to maximize antigen expres-
sion (Schmidt et al., 2002). Recombinants were made
representing both RSV antigenic subgroups (Fig. 3). The
chimeric rB/HPIV3-RSV viruses replicated efficiently in
vitro and expressed high levels of the RSV G and F
glycoproteins. For example, the rB/HPIV3-G chimera ex-
pressed several-fold more G protein than either the RSV
or the vaccinia-G recombinant mentioned above. When
inoculated into the respiratory tract of rhesus monkeys,
the rB/HPIV3-RSV chimeras were somewhat more atten-
uated than their rB/HPIV3 parent, presumably due to the
FIG. 3. Gene map illustrating the construction of bivalent chimeric
recombinant rB/HPIV3-RSV viruses expressing RSV F and/or G from
added gene inserts. In the rB/HPIV3 backbone, BPIV3-derived genes
are shown as open boxes while the HPIV3-derived F and HN genes are
filled (Schmidt et al., 2000). The G and/or F genes of RSV strains B1 or
A2 (hatched boxes) were added as promoter-proximal inserts (arrow).
Transcription signals are shown as black vertical bars; leader, trailer,
and intergenic regions are shown as a light horizontal line.
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presence of the insert(s), but nonetheless were highly
immunogenic against both RSV and HPIV3. As another
example, recombinant VSVs were constructed that ex-
press RSV G or F, either as added genes or in place of
the single VSV glycoprotein G, but were poorly immuno-
genic in mice (Kahn et al., 2001). This suggests that the
biological characteristics of the vector virus, rather than
efficient expression alone, are important determinants of
immunogenicity and protective efficacy.
The rB/HPIV3-RSV-A and -B chimeric viruses provide a
trivalent pediatric vaccine against RSV-A, RSV-B, and
HPIV3. HPIV3 is second only to RSV in importance as a
pediatric viral respiratory tract pathogen. Thus, the vector
itself is a needed vaccine rather than simply a carrier.
RSV and HPIV3 cause disease in approximately the
same age group, and hence it is desirable to have a
combined RSV/HPIV3 vaccine. Similar to RSV, PIV3 is
pneumotropic and thus is well suited as a vector for
intranasal immunization. PIV3 should be an extremely
safe vector since it does not cause disease outside of
the respiratory tract, and since the nonpediatric popula-
tion has immunity to HPIV3. There is considerable expe-
rience in administering PIV3 to children and infants.
These advantages do not hold for most other potential
vectors for RSV antigens. Interestingly, the rB/HPIV3-RSV
chimeric viruses were not neutralized by RSV-specific
antibodies, raising the possibility that a PIV-vectored RSV
vaccine might be particularly useful as a booster immu-
nization in infants previously immunized with an RSV
vaccine.
In conclusion, a number of promising live-attenuated
RSV strains produced by reverse genetics are undergo-
ing clinical evaluation as candidate vaccines for young
infants. Two promising protein vaccines, one of which is
of recombinant origin, are being evaluated as booster
vaccines for RSV-experienced children and adults. A
less-attenuated live RSV vaccine also could be used in
these groups. Multivalent live vectored vaccines might
simplify and expedite vaccine development and admin-
istration. The development of safe and effective RSV
vaccines would benefit from a more complete under-
standing of RSV immunobiology, in particular, why immu-
nity to RSV is less complete and durable compared to
that, for example, of influenza virus or rhinovirus.
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